Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co’s asthma drug Singulair faces US generic onslaught

FDA licenses versions of the brand from Teva, Sandoz, Aurobindo Pharma and others

The Food and Drug Administration (FDA) has approved the first generic versions of Merck & Co's blockbuster asthma and allergy drug Singulair.

The US regulator granted ten companies licences to market their own version of Singulair (motelukast) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

Gregory Geba, director of the Office of Generic Drugs in FDA's Center for Drug Evaluation and Research, said: “For people who suffer from chronic health conditions such as asthma and allergies, it is important to have effective and affordable treatment options. The generic products approved will expand those options for patients.”

Montelukast is a leukotriene receptor antagonist and blocks leukotrienes; the substance that causes asthma and hay fever (allergic rhinitis) symptoms.

In the first three months of this year the drug was the fourth biggest selling pharma brand and in the second quarter it brought in $1.4bn, continuing its run as Merck's biggest selling product.

But the approval of a swathe of generic competitors in the world's biggest pharma market is sure to decimate Merck's sales.

The FDA licensed generic motelukast tablets from Apotex, Aurobindo Pharma, Endo Pharmaceuticals, Glenmark Generics, Kudco Ireland, Mylan, Roxane Laboratories, Sandoz, Teva Pharmaceuticals and Torrent Pharmaceuticals.

The regulator also gave the go-ahead for chewable tablets from Apotex, Aurobindo, Endo, Kudco, Mylan, Roxane, Sandoz, Teva, and Torrent, and an oral granule form of the drug from Teva.

Montelukast Sodium Tablets, 10 mg, had US sales of approximately $3.7bn for the 12 months ending June 30, 2012, and Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, had US sales of approximately $1.2bn for the 12 months ending June 30, 2012, according to IMS Health. 

Generic prescribing in the US last year saw its largest year-on-year increase since 1998 according to another IMS study that found nearly 80 per cent of prescriptions in the country are now written generically.

8th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

How to create a multi-channel marketing strategy and plan
You know what it is and why you need one, now find out how to create a successful pharma multi-channel marketing strategy and plan...
Biosimilars: Getting the flock to market
The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd...
Creative effectiveness: how to achieve tangible results
Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market....

Infographics